“On October 6, 2010, after two hours of deliberation, a New Brunswick jury returned a 7-2 verdict in favor of Novartis Pharmaceuticals Corporation in a 10-day trial involving Aredia® and Zometa®, bisphosphonate drugs given to people whose cancer has metastasized to their bones. Novartis was represented by DRI members Joe G. Hollingsworth and Katharine R. Latimer of Hollingsworth LLP and Beth Rose of Sills Cummis & Gross.”
